Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.

Humans Mice Animals Receptors, Antigen, T-Cell / genetics Cross-Priming Gastrointestinal Microbiome Vancomycin / pharmacology Immunotherapy T-Lymphocytes Immunotherapy, Adoptive / methods Receptors, Chimeric Antigen / genetics Antigens, CD19
CAR T cell antigen cross-presentation gut microbiota immunotherapy vancomycin

Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 01 04 2022
revised: 20 10 2022
accepted: 10 01 2023
pmc-release: 01 03 2024
pubmed: 16 1 2023
medline: 7 3 2023
entrez: 15 1 2023
Statut: ppublish

Résumé

Several studies have shown the influence of commensal microbes on T cell function, specifically in the setting of checkpoint immunotherapy for cancer. In this study, we investigated how vancomycin-induced gut microbiota dysbiosis affects chimeric antigen receptor (CAR) T immunotherapy using multiple preclinical models as well as clinical correlates. In two murine tumor models, hematopoietic CD19

Identifiants

DOI: 10.1016/j.ymthe.2023.01.012 PMID: 36641624 PMC: PMC10014349
pubmed: 36641624
pii: S1525-0016(23)00012-6
doi: 10.1016/j.ymthe.2023.01.012
pmc: PMC10014349
pii:
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0
Vancomycin 6Q205EH1VU
Receptors, Chimeric Antigen 0
Antigens, CD19 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

686-700

Subventions

Organisme : NCI NIH HHS
ID : R01 CA206012
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219871
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests M.R.: BMS, BAYER, GSK, consultancy; Novartis, patents and royalties; AbClon, consultancy, research funding; Tmunity, patents and royalties; viTToria Biotherapeutics, research funding. N.F.: Sana Biotechnology, consultancy; Novartis, research funding; Kite Pharma, consultancy; Syndax Pharmaceuticals, consultancy. C.H.J.: Tmunity, DeCART, BluesphereBio, Carisma, Cellares, Celldex, Cabaletta, Poseida, Verismo, and Ziopharm, current equity holder in publicly traded company; AC Immune, DeCART, BluesphereBio, Carisma, Cellares, Celldex, Cabaletta, Poseida, Verismo, Ziopharm, consultancy; Novartis, patents and royalties. D.L.P.: American Society for Transplantation and Cellular Therapy, honoraria; ASH and DeCart, membership on the Board of Directors or advisory committee; Genentech, current employment, current equity holder in publicly traded company; Incyte and Janssen, Kite/Gilead, and National Marrow Donor Program, membership on an entity’s board of directors or advisory committee; Novartis, membership on an entity’s board of directors or advisory committee, patents and royalties, and research funding; Unity, patents and royalties; and Wiley and Sons Publishing, honoraria. S.J.S.: TG Therapeutics, research funding; Incyte, research funding; Adaptive Biotechnologies, research funding; Pharmacyclics, research funding; Merck, research funding; Genentech/Roche, consultancy, research funding; Tessa Therapeutics, consultancy; Loxo Oncology, consultancy; Juno Therapeutics, consultancy, research funding; BeiGene, consultancy; Alimera Sciences, consultancy; Acerta Pharma/AstraZeneca, consultancy; Novartis, consultancy, honoraria, patents and royalties, research funding; AbbVie, consultancy, research funding; Nordic Nanovector, consultancy; Celgene, consultancy, honoraria, research funding.

Références

Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Cell Mol Immunol. 2021 May;18(5):1161-1171
pubmed: 33850311
Nat Rev Immunol. 2009 Jul;9(7):503-13
pubmed: 19498380
Blood. 2014 Nov 13;124(20):3081-91
pubmed: 25100743
J Clin Oncol. 2020 Feb 10;38(5):415-422
pubmed: 31815579
Nat Commun. 2020 Dec 2;11(1):6171
pubmed: 33268774
Nat Commun. 2020 Dec 4;11(1):6217
pubmed: 33277504
Cancers (Basel). 2019 Apr 11;11(4):
pubmed: 30979057
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Scand J Infect Dis. 2011 May;43(5):386-8
pubmed: 21198337
Cells. 2021 Dec 20;10(12):
pubmed: 34944095
Cell Rep. 2017 Sep 26;20(13):3025-3033
pubmed: 28954221
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
N Engl J Med. 2021 Feb 18;384(7):673-674
pubmed: 33596362
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Nat Med. 2021 Aug;27(8):1432-1441
pubmed: 34239137
Cancer Lett. 2019 Apr 10;447:41-47
pubmed: 30684593
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Nat Rev Immunol. 2017 Apr;17(4):219-232
pubmed: 28260787
Front Immunol. 2019 Dec 17;10:2965
pubmed: 31921205
Nat Commun. 2021 Jul 1;12(1):4077
pubmed: 34210970
Cell Commun Signal. 2020 Jun 10;18(1):90
pubmed: 32522267
Sci Rep. 2017 Nov 6;7(1):14516
pubmed: 29109552
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Front Public Health. 2014 Oct 31;2:217
pubmed: 25401098
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Antimicrob Agents Chemother. 1978 Oct;14(4):634-5
pubmed: 718158
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Nat Rev Immunol. 2020 Jul;20(7):411-426
pubmed: 32005980
Cell Immunol. 2004 Apr;228(2):130-7
pubmed: 15219464
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467322
Annu Rev Immunol. 2016 May 20;34:93-119
pubmed: 26735697
Nat Commun. 2020 Oct 15;11(1):5206
pubmed: 33060586
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33496784
Front Immunol. 2013 Nov 11;4:371
pubmed: 24273543
Lancet. 1978 Jul 29;2(8083):226-8
pubmed: 79026
J Immunol. 2002 Oct 1;169(7):3908-13
pubmed: 12244189
J Clin Microbiol. 2005 Aug;43(8):4041-5
pubmed: 16081948
Front Immunol. 2018 Jul 16;9:1643
pubmed: 30061897
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385
pubmed: 30837712
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Radiat Oncol. 2021 Jan 13;16(1):9
pubmed: 33436010
JCI Insight. 2017 Nov 16;2(22):
pubmed: 29202455
J Clin Invest. 2020 Jan 2;130(1):466-479
pubmed: 31815742
Nat Immunol. 2015 Jul;16(7):708-17
pubmed: 26054719
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2021 Feb 5;371(6529):595-602
pubmed: 33542131
J Antimicrob Chemother. 1989 Jan;23(1):167-9
pubmed: 2745253
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33563772
Front Genet. 2019 Sep 25;10:858
pubmed: 31608109
Nat Commun. 2019 Feb 15;10(1):760
pubmed: 30770822
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358

Auteurs

Mireia Uribe-Herranz (M)

Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Immunology Department, Hospital Clínic of Barcelona, Barcelona 08036, Spain.

Silvia Beghi (S)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

Marco Ruella (M)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Kalpana Parvathaneni (K)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Silvano Salaris (S)

Unit of Biostatistics, Epidemiology and Public Health, University of Padova, Padova, Italy.

Nektarios Kostopoulos (N)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

Subin S George (SS)

Bioinformatics Core, Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Stefano Pierini (S)

Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA; The Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Elisavet Krimitza (E)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

Francesca Costabile (F)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

Guido Ghilardi (G)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Kimberly V Amelsberg (KV)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Yong Gu Lee (YG)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Raymone Pajarillo (R)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Caroline Markmann (C)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Bevin McGettigan-Croce (B)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Divyansh Agarwal (D)

Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

Noelle Frey (N)

Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Simon F Lacey (SF)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

John Scholler (J)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Khatuna Gabunia (K)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Gary Wu (G)

Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Elise Chong (E)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

David L Porter (DL)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Carl H June (CH)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Stephen J Schuster (SJ)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Vijay Bhoj (V)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Andrea Facciabene (A)

Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA; The Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: andrea.facciabene@pennmedicine.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Modulation of the gut microbiota engages...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Modulation of the gut microbiota engages...
questionsmedicales.fr › Eucaryotes › Animaux › Modulation of the gut microbiota engages...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux antigènes › Récepteurs aux antigènes des cellules T › Modulation of the gut microbiota engages...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › Cross-priming › Modulation of the gut microbiota engages...
questionsmedicales.fr › Environnement et santé publique › Environnement › Écosystème › Biodiversité › Biote › Microbiote › Microbiome gastro-intestinal › Modulation of the gut microbiota engages...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › Modulation of the gut microbiota engages...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Modulation of the gut microbiota engages...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Modulation of the gut microbiota engages...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Modulation of the gut microbiota engages...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs chimériques pour l'antigène › Modulation of the gut microbiota engages...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD19 › Modulation of the gut microbiota engages...